LEO Pharma A/S - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 100

LEO Pharma A/S – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “LEO Pharma A/S - Product Pipeline Review - 2012” provides data on the LEO Pharma A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, LEO Pharma A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from LEO Pharma A/S and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- LEO Pharma A/S - Brief LEO Pharma A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of LEO Pharma A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of LEO Pharma A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the LEO Pharma A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate LEO Pharma A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of LEO Pharma A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the LEO Pharma A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with LEO Pharma A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of LEO Pharma A/S and identify potential opportunities in those areas.

Keyword

Current R&D Portfolio of LEO Pharma A/S; LEO Pharma A/S - Key Therapeutics; LEO Pharma A/S - Pipeline Overview and Promising Molecules; LEO Pharma A/S - News; LEO Pharma A/S - Latest Updates; LEO Pharma A/S - Pipeline; LEO Pharma A/S - Discontinued/Dormant Projects

List of Tables
List of Figures
LEO Pharma A/S Snapshot
LEO Pharma A/S Overview
Key Information
Key Facts
LEO Pharma A/S – Research and Development Overview
Key Therapeutic Areas
LEO Pharma A/S – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
LEO Pharma A/S – Pipeline Products Glance
LEO Pharma A/S – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
LEO Pharma A/S Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
LEO Pharma A/S – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
LEO Pharma A/S – Drug Profiles
LEO 22811
Product Description
Mechanism of Action
R&D Progress
LEO 27847
Product Description
Mechanism of Action
R&D Progress
LEO 27989
Product Description
Mechanism of Action
R&D Progress
LEO 27989 + Calcipotriol
Product Description
Mechanism of Action
R&D Progress
LEO 29102
Product Description
Mechanism of Action
R&D Progress
LEO 80185 Topical Suspension
Product Description
Mechanism of Action
R&D Progress
LEO 90100
Product Description
Mechanism of Action
R&D Progress
LEO 90105
Product Description
Mechanism of Action
R&D Progress
LEO 90110
Product Description
Mechanism of Action
R&D Progress
LP 0058
Product Description
Mechanism of Action
R&D Progress
LP 0067
Product Description
Mechanism of Action
R&D Progress
Picato
Product Description
Mechanism of Action
R&D Progress
VBY-891
Product Description
Mechanism of Action
R&D Progress
LEO Pharma A/S – Pipeline Analysis
LEO Pharma A/S – Pipeline Products by Therapeutic Class
LEO Pharma A/S – Pipeline Products By Target
LEO Pharma A/S – Pipeline Products by Route of Administration
LEO Pharma A/S – Pipeline Products By Mechanism of Action
LEO Pharma A/S – Recent Pipeline Updates
LEO Pharma A/S - Dormant Projects
LEO Pharma A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CB1089
LEO 80190
Picato
TD1414
LEO Pharma A/S – Company Statement
LEO Pharma A/S – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
LEO Pharma A/S, Recent Developments
LEO Pharma A/S- Press Release
Mar 14, 2012: New England Journal Of Medicine Reviews Benefits Of Leo Pharma's Ingenol Mebutate In Treatment Of Actinic Keratosis
Jan 25, 2012: FDA Approves LEO Pharma's Picato Gel For Topical Treatment Of Actinic Keratosis
Dec 21, 2009: LEO Pharma Announces Positive Phase III Study Results Of PEP005 For The Treatment Of Lesions On Head Treatment Areas
Aug 19, 2009: Peplin Completes Enrolment In Its Final Phase III Clinical Trial For PEP005 Gel In AK
Jul 23, 2009: Peplin Initiates Its Final Phase III Clinical Trial For PEP005 Gel In AK
Jun 08, 2009: Peplin Announces The Initiation Of Phase 3 Clinical Trials For PEP005 Gel In AK On The Face And Scalp
Jun 04, 2009: LEO Pharma to expand in Russian market
May 27, 2009: Peplin’s Successful Phase II AK Trial Results Published In JAAD
May 17, 2009: Positive Results For Peplin’s First Phase III AK Trial
May 06, 2009: ATryn Available for Patients with Hereditary Antithrombin Deficiency, a Rare Blood Clotting Disorder
May 06, 2009: GTC Biotherapeutics Reports Launch of Atryn in the U.S. by Lundbeck Inc.
Mar 30, 2009: GTC Biotherapeutics Reports Progress in Preparations to Launch Atryn in the U.s.
Mar 13, 2009: GTC Biotherapeutics Provides Update on Agreement with Leo Pharma A/S
Mar 09, 2009: GTC Biotherapeutics Reports Progress in Atryn Program in U.S
Mar 06, 2009: Peplin’s Positive Phase IIb AK Trial Result Details
Feb 06, 2009: ATryn (Antithrombin [Recombinant]) Approved by the FDA
Jan 28, 2009: Leo Pharma wins a litigation with generic drug manufacturer Kotra Pharma in Malaysia
Jan 09, 2009: FDA Advisory Committee Recommends GTC Biotherapeutics' ATryn (antithrombin [Recombinant]) If approved, ATryn will be first recombinant human antithrombin available in the U.S
Jan 08, 2009: Positive Results For Peplin’s Phase IIb AK Trial
Financial Deals Landscape
LEO Pharma A/S, Deals Summary
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
LEO Pharma Acquires US Rights Of Psoriasis Portfolio And Dermatology Pipeline From Warner Chilcott
Partnerships
LEO Pharma Enters Into Research Collaboration With The Scripps Research Institute
LEO Pharma Enters Into Co-Marketing Agreement With Nycomed International Management
LEO Pharma Enters Into Agreement With Galapagos
LEO Pharma Signs An Agreement With Foamix
GTC Biotherapeutics Enters Into Collaboration With LEO Pharma
Licensing Agreements
LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug
Gemin X Biotechnologies Enters Into Licensing Agreement With LEO Pharma
LEO Pharma Enters Into Licensing Agreement With TopoTarget
LEO Pharma Enters Into Licensing Agreement With Cougar Biotech
Alliance Pharma Extends Licensing Agreement With LEO Pharma
Equity Offering
Peplin Completes Private Placement Of $24 Million
Peplin Completes Private Placement Of $5.6 Million
Peplin Completes Private Placement Of $11.4 Million
Peplin Completes Private Placement Of $20 Million
Peplin Completes Rights Offering For $11 Million
Peplin Completes Private Placement Of $3.05 Million
Peplin Completes Rights Offering For $7.8 Million
Asset Transactions
Recip Acquires Malvitona From LEO Pharma
Acquisition
LEO Pharma Acquires Peplin
Immuno-Biological Labs Acquires NEOSILK
Peplin Acquires Neosil
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
LEO Pharma A/S, Key Information
LEO Pharma A/S, Key Facts
LEO Pharma A/S – Pipeline by Indication, 2012
LEO Pharma A/S – Pipeline by Stage of Development, 2012
LEO Pharma A/S – Monotherapy Products in Pipeline, 2012
LEO Pharma A/S – Combination Treatment Modalities in Pipeline, 2012
LEO Pharma A/S – Phase III, 2012
LEO Pharma A/S – Phase II, 2012
LEO Pharma A/S – Phase I, 2012
LEO Pharma A/S – Pre-Clinical, 2012
LEO Pharma A/S – Pipeline By Therapeutic Class, 2012
LEO Pharma A/S - Pipeline By Target, 2012
LEO Pharma A/S – Pipeline By Route of Administration, 2012
LEO Pharma A/S – Pipeline Products By Mechanism of Action, 2012
LEO Pharma A/S – Recent Pipeline Updates, 2012
LEO Pharma A/S - Dormant Developmental Projects,2012
LEO Pharma A/S - Discontinued Pipeline Products, 2012
LEO Pharma A/S, Subsidiaries
LEO Pharma A/S, Deals Summary
LEO Pharma Acquires US Rights Of Psoriasis Portfolio And Dermatology Pipeline From Warner Chilcott
LEO Pharma Enters Into Research Collaboration With The Scripps Research Institute
LEO Pharma Enters Into Co-Marketing Agreement With Nycomed International Management
LEO Pharma Enters Into Agreement With Galapagos
LEO Pharma Signs An Agreement With Foamix
GTC Biotherapeutics Enters Into Collaboration With LEO Pharma
LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug
Gemin X Biotechnologies Enters Into Licensing Agreement With LEO Pharma
LEO Pharma Enters Into Licensing Agreement With TopoTarget
LEO Pharma Enters Into Licensing Agreement With Cougar Biotech
Alliance Pharma Extends Licensing Agreement With LEO Pharma
Peplin Completes Private Placement Of $24 Million
Peplin Completes Private Placement Of $5.6 Million
Peplin Completes Private Placement Of $11.4 Million
Peplin Completes Private Placement Of $20 Million
Peplin Completes Rights Offering For $11 Million
Peplin Completes Private Placement Of $3.05 Million
Peplin Completes Rights Offering For $7.8 Million
Recip Acquires Malvitona From LEO Pharma
LEO Pharma Acquires Peplin
Immuno-Biological Labs Acquires NEOSILK
Peplin Acquires Neosil

List of Figures
LEO Pharma A/S – Pipeline by Indication, 2012
LEO Pharma A/S – Pipeline by Stage of Development, 2012
LEO Pharma A/S – Monotherapy Products in Pipeline, 2012
LEO Pharma A/S – Combination Treatment Modalities in Pipeline, 2012
LEO Pharma A/S – Pipeline By Therapeutic Class, 2012
LEO Pharma A/S - Pipeline By Target, 2012
LEO Pharma A/S – Pipeline By Route of Administration, 2012
LEO Pharma A/S - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• LeoNovus Inc.,(LTV) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Amazon - Point of Realization in 2013?
• Scientific Games Corporation - Company Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model